Strides Arcolab Limited has announced that the company has got FDA approval for its Ergocalciferol soft capsules to treat Vitamin D resistant rickets.
The capsules would be launched in the US market in soft gelatin form with 1.25 mg strength in bottles of 50 and 100.
The company's Vice Chairman and Group CEO, Mr Arun Kumar said, "Strides is among the few soft gelatin manufacturers focusing on the prescription drug domain, and we are delighted with this important and first soft gelatin product approval by the USFDA."
IMS data estimates say in 2009 that the total US market was around 62.9 million.
"The product will be marketed and sold by Paddock Laboratories Inc under a profit share partnership, and the product would be launched immediately." he further added.
Ergocalciferol capsules are used for treating hypoparathyroidism, refractory rickets alternatively called Vitamin D resistant rickets or familial hypophosphatemia.
Shares of Strides Arcolab at the Bombay Stock Exchanges by 2.83 per cent to hit an all—time high of Rs 465.95.
